Compared with their un-mutated counterparts, TET2-mutated cases were less likely to have a low hemoglobin (P<0.001), include CMML-2 (P=0.007), have circulating immature myeloid cells (P=0.001), have peripheral blood (P=0.009) and BM blasts (P=0.009), and have higher-risk stratification per clinical, cytogenetic and molecularly inclusive CMML prognostic models (Table 1); these differences were not affected by the type or number of TET2 mutations. Here, TET2 is linked to chronic myelomonocytic leukemia.